Bone graft and scaffolding materials immobilized with osteogenesis enhancing peptides on the surface
    1.
    发明授权
    Bone graft and scaffolding materials immobilized with osteogenesis enhancing peptides on the surface 有权
    骨移植物和脚手架材料固定在骨形成增强肽表面

    公开(公告)号:US07897163B2

    公开(公告)日:2011-03-01

    申请号:US10593430

    申请日:2005-03-18

    摘要: The present invention relates to a bone graft material and a scaffold for tissue engineering applications, which have an osteogenesis-promoting peptide immobilized on the surface. More particularly, the invention relates to a bone graft material and a scaffold for tissue engineering applications, which have a cell adhesion-inducing peptide and/or tissue growth factor-derived peptide immobilized on the surface. By the osteogenesis-promoting peptide immobilized on the surface, the inventive bone graft material and scaffold for tissue engineering applications can promote the transition, proliferation and differentiation of cells associated with regeneration, and eventually maximize the regeneration of tissue. Moreover, the peptide immobilized on the surface has low molecular weight, indicating a reduced risk of immune responses upon its application in the body, and can be present in a stable form within the body, thus showing lasting effects. Accordingly, the peptide makes it expedient to perform surgical operations for the regeneration of periodontal tissue, alveolar bone and other bone tissues, and will show high therapeutic effect.

    摘要翻译: 本发明涉及用于组织工程应用的骨移植材料和支架,其具有固定在表面上的成骨促进肽。 更具体地,本发明涉及用于组织工程应用的骨移植材料和支架,其具有固定在表面上的细胞粘附诱导肽和/或组织生长因子衍生的肽。 通过固定在表面上的成骨促进肽,本发明的骨移植材料和用于组织工程应用的支架可以促进与再生有关的细胞的转化,增殖和分化,并且最终使组织的再生最大化。 此外,固定在表面上的肽具有低分子量,表明其在体内应用时免疫应答的风险降低,并且可以以体内的稳定形式存在,从而显示出持久的效果。 因此,肽对于进行牙周组织,牙槽骨等骨组织的再生的外科手术是有利的,并且将显示出高疗效。

    Mucoadhesive nanocomposite delivery system
    2.
    发明申请
    Mucoadhesive nanocomposite delivery system 审中-公开
    粘膜纳米复合物输送系统

    公开(公告)号:US20090232899A1

    公开(公告)日:2009-09-17

    申请号:US11596934

    申请日:2005-05-20

    摘要: A nanocomposite delivery system uses chitosan as a mucoadhesive material encapsulated in a surface modified network of colloidal nanoporous nanoparticles, such as silica, or other colloid-forming materials, especially metal oxides. Drug delivery systems may be provided by binding a drug to the chitosan/silica nanocomposite, typically by adding a drug or other active agent during in-situ gellation of colloidal silica. When the active agent is, for example, amoxicillin or other antibiotic agent, the drug delivery system may be used in the treatment of stomach ulcers, for example.

    摘要翻译: 纳米复合物递送系统使用壳聚糖作为胶体纳米多孔纳米颗粒(如二氧化硅)或其他形成胶体的材料,特别是金属氧化物的表面改性网络中的粘膜粘附材料。 药物递送系统可以通过将药物与壳聚糖/二氧化硅纳米复合物结合来提供,通常通过在胶体二氧化硅的原位凝胶化过程中加入药物或其它活性剂。 当活性剂是例如阿莫西林或其它抗生素时,药物递送系统可用于例如胃溃疡的治疗。